REMARKS

I. INTRODUCTION

Receipt of the Office Action of August 1, 2001 is acknowledged. New claims 57-105 have been added. Support for the claim amendments can be found generally throughout the specification and original claims, for example, original claims 33, 41, 48 and 52 as well as claims 6, 8, 10, 12, 14, 16, 17, 18, 19, 20, 21, 22, 24, 26, 28, 29.

II. STATUS OF THE CLAIMS

Claims 1-53 and 57-105 are pending in this application.

III. THE RESTRICTION REQUIREMENT

Applicants elect with traverse Group B, claims 40-53 for examination on the merits. The traversal is on the ground that the IPER corresponding to the present application did not find a lack of unity of invention. Similarly, the present application does not lack unity of invention contrary to the Examiner's assertions. Furthermore, claims 30-39 and the new claims should be included within the elected group because claims 30-39 relate to a preservation solution of the $sPLA_2$ inhibitor composition and a method of use of the $sPLA_2$ inhibitor composition.

IV. CONCLUSION

For the foregoing reasons, the rejections should be withdrawn, and claims 23-44 should be allowed. Early and favorable action in that regard is earnestly solicited.

Should the Examiner have any questions concerning this Amendment, or wish to discuss any other issues in an effort to advance the prosecution of this application to issue, the Examiner is requested to contact the undersigned at the telephone number below.

It is believed that no fee is due, but should such a fee be due, consider this paragraph a request and authorization to charge the appropriate fee to Deposit Account No. 19-0741.

Respectfully submitted,

Date Feb. 15, 2002 By Mary C Till

FOLEY & LARDNER
Washington Harbour
3000 K Street, N.W., Suite 500
Washington, D.C. 20007-5109
Telephone: (202) 672-5300
Facsimile: (202) 672-5399

Mary C. Till
Agent for Applicant
Registration No. 41,545

VERSION WITH MARKINGS TO SHOW CHANGES MADE

41. (Twice Amended) A method for preventing ischemia reperfusion injury of claim [30] 35, wherein the $sPLA_2$ inhibitor is a compound which contains a compound as an active ingredient, which is represented by the formula (I):



(I)

wherein R^1 is a group selected from (a) C7 to C20 alkyl, C7 to C20 alkenyl, C7 to C20 alkynyl, carbocyclic groups, and heterocyclic groups, (b) the groups represented by (a) each substituted independently with at least one group selected from non-interfering substituents, and (c) $-(L^1)-R^7$ wherein L^1 is a divalent linking group of 1 to 18 atom(s) selected from hydrogen atom(s), nitrogen atom(s), carbon atom(s), oxygen atom(s), and sulfur atom(s), wherein the combination atoms in L^1 are selected from the group consisting of i) carbon and hydrogen, ii) sulfur only, iii) oxygen only, iv) nitrogen and hydrogen only, v) carbon, hydrogen, and sulfer only, and vi) carbon, hydrogen, and oxygen only and R^7 is a group selected from the groups (a) and (b);

R^2 is hydrogen atom, halogen, C1 to C3 alkyl, C3 to C4 cycloalkyl, C3 to C4 cycloalkenyl, C1 to C3 alkyloxy, or C1 to C3 alkylthio;

R^3 and R^4 are each independently hydrogen atom, non-interfering substituents, or $-(L^2)-$(acidic group) wherein L^2 is an acid linker having an acid linker length of 1 to 5, provided that one of R^3 and R^4 is $-(L^2)-$(acidic group);

R^5 and R^6 are each independently hydrogen atom, non-interfering substituents, carbocyclic groups, carbocyclic groups substituted with a non-interfering substituent(s), heterocyclic groups, or heterocyclic groups substituted with a non-interfering substituent(s); and

R^A is a group represented by the formula:



wherein R^8 and R^9 are each independently hydrogen atom, C1 to C3 alkyl or halogen; X and Y are each independently oxygen atom or sulfur atom; and Z is $-NH_2$ or $-NHNH_2$; the prodrugs thereof; their pharmaceutically acceptable salts; or their hydrates.